Moleculin Biotech IncNASDAQ:MBRX
- LAST PRICE3.5200
- TODAY'S CHANGE (%)0.1000 (2.9240%)
- Bid / Lots3.5000/ 9
- Ask / Lots4.0000/ 2
- Open / Previous Close3.4600 / 3.4200
- Day Range
- 52 Week Range
- Volume9,488
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBRX |
|---|---|---|
| 09:32 ET | 332 | 3.46 |
| 09:59 ET | 100 | 3.54 |
| 10:19 ET | 208 | 3.54 |
| 10:37 ET | 1750 | 3.36 |
| 10:39 ET | 100 | 3.36 |
| 10:46 ET | 200 | 3.425 |
| 01:28 ET | 134 | 3.5 |
| 01:48 ET | 100 | 3.42 |
| 01:51 ET | 128 | 3.505 |
| 01:53 ET | 100 | 3.43 |
| 03:00 ET | 100 | 3.51 |
| 03:02 ET | 100 | 3.6099 |
| 03:45 ET | 2067 | 3.5 |
| 03:50 ET | 100 | 3.51 |
| 03:52 ET | 100 | 3.51 |
| 03:54 ET | 100 | 3.51 |
| 03:59 ET | 100 | 3.52 |
Jul 22, 2024
*DJ Moleculin Biotech Files to Offer Stock and Warrants, from 5:46PM ET on Monday Jul 22, 2024 by Dow Jones
5:46PM ET on Monday Jul 22, 2024 by Dow Jones
Jul 10, 2024
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML, from 8:30AM ET on Wednesday Jul 10, 2024 by Dow Jones
8:30AM ET on Wednesday Jul 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Moleculin Biotech Inc | 7.9M | -0.3x | --- |
National Graphite Corp | 7.9M | -2.4x | --- |
GlucoTrack Inc | 7.8M | -0.7x | --- |
Vaxxinity Inc | 7.6M | -0.1x | --- |
Weed Inc | 8.3M | -6,700.0x | --- |
Chromocell Therapeutics Corp | 7.4M | -0.9x | --- |
Company Information
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Contact Information
- Headquarters
- 5300 Memorial Dr Ste 950HOUSTON, TX, United States 77007-8274
- Phone
- 713-300-5160
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Walter Klemp
- Chief Financial Officer, Executive Vice President
- Jonathan Foster
- Chief Scientific Officer
- Donald Picker
- Senior Chief Medical Officer
- Paul Waymack
- Independent Director
- Michael Cannon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-12.94 |
Book Value | $11.70 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
